|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.7 CHF | -0.41% |
|
+1.66% | +16.30% |
| 15/07 | Brace for a flurry of speeches from Fed officials |  |
| 15/07 | European companies cut jobs as economy sputters | RE |
Jan 2 (Reuters) - Voyager Therapeutics said on Tuesday Novartis would pay it $100 million upfront in cash as part of a licensing deal to develop gene therapy candidates. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,150 PTS | +0.77% | +3.24% | - | ||
| 98.68 CHF | -0.42% | +1.66% | 226B | ||
| 8.96 USD | +2.17% | +15.02% | 487M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +16.30% | 226B | |
| +63.05% | 856B | |
| +39.09% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +13.49% | 244B | |
| +5.28% | 234B | |
| +14.63% | 177B | |
| +1.08% | 165B |
NOVARTIS AG 
